| Project/Area Number |
23659057
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
MORIOKA Hiroshi 熊本大学, 大学院・生命科学研究部, 教授 (20230097)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUWA Yoshiaki 熊本大学, 薬学部, 特任助教 (50516127)
|
|---|
| Research Collaborator |
ITOH Teiji 株式会社 岸本医学研究所, 苫小牧ラボ, 主席研究員
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 薬学 / AGE 認識抗体 / 分子進化工学 / ファージディスプレイ / scFv 抗体 / 低分子抗原 / デンドリマー型ペプチド / AGE認識抗体 / scFv抗体 / SPRバイオセンサー / 熱力学的解析 |
|---|
| Research Abstract |
It has been proposed that formation and accumulation of advancedglycation end products (AGEs) in various tissues are involved in atherosclerosis,diabetic complications and aging-associated diseases. In order to determine AGEsaccumulation in various pathological tissues, immunological studies using monoclonalanti-AGE antibodies are highly effective. However, only a few of antibodies against AGEshave been established at present. Actually, it is not easy to prepare monoclonalantibodies that have high-affinity and high-specificity against AGEs, because of thediversity and heterogeneity of AGE structures and their small molecular sizes. Therefore,we have conducted protein-engineering approaches to develop recombinant antibodies withhigh affinity for various kinds of AGEs. In the present study, we have carried out phagedisplay experiments to prepare single-chain antibodies (scFvs) specific for one of AGEstructure, GA-pyridine
|
